Rchr
J-GLOBAL ID:201901012759819288
Update date: Apr. 20, 2024
Nakamura Sou
Nakamura Sou
Research field (1):
Biomedical engineering
Research theme for competitive and other funds (5):
- 2021 - 2026 Elucidating the fundamental mechanism of platelet biogenesis and its medical application
- 2022 - 2025 巨核球成熟における一次絨毛由来小胞の生理機能解明および生体外血小板製造への応用
- 2021 - 2022 流体刺激シグナルの解明に基づく連続血小板製造非定常培養機器の開発
- 2018 - 2022 New method for establishing self-renewing megakaryocyte cell lines using iPS cells
- 2018 - 2021 Mechanism of turbulence mediated platelet biogenesis and application to ex vivo manufacturing of platelets
Papers (31):
-
Si Jing Chen, Kazuya Hashimoto, Kosuke Fujio, Karin Hayashi, Sudip Kumar Paul, Akinori Yuzuriha, Wei-Yin Qiu, Emiri Nakamura, Maria Alejandra Kanashiro, Mio Kabata, et al. A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility. Nature Communications. 2024. 15. 1
-
Charlotte Flahou, Tatsuya Morishima, Natsumi Higashi, Yoshikazu Hayashi, Huaigeng Xu, Bo Wang, Chaoqi Zhang, Atsushi Ninomiya, Wei-Yin Qiu, Akinori Yuzuriha, et al. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells. Biochemical and biophysical research communications. 2023. 662. 76-83
-
林 智也, 三島 優一, 中村 壮, 杉本 直志, 堀田 秋津, 正木 美香子, 田中 光信, 石井 博之, 立山 英美, 藤村 吉博, et al. ゲノム編集技術を用いたiPS細胞由来特異的HPA発現パネル細胞株の開発 HPA-3a抗体の特異的な検出. 日本輸血細胞治療学会誌. 2023. 69. 2. 283-283
-
Naoshi Sugimoto, Sou Nakamura, Shin Shimizu, Akiko Shigemasa, Junya Kanda, Nobuki Matsuyama, Mitsunobu Tanaka, Tomoya Hayashi, Akihiro Fuchizaki, Masayuki Nogawa, et al. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial. Blood advances. 2022. 6. 23. 6056-6069
-
Naoshi Sugimoto, Junya Kanda, Sou Nakamura, Toshiyuki Kitano, Masakatsu Hishizawa, Tadakazu Kondo, Shin Shimizu, Akiko Shigemasa, Hideyo Hirai, Yasuyuki Arai, et al. iPLAT1: The first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study. Blood. 2022. 140. 22. 2398-2402
more...
MISC (33):
-
中村 壮, 江藤 浩之. 【ヒトの再生をめぐる諸問題】iPS細胞由来血小板製剤の開発. HORMONE FRONTIER IN GYNECOLOGY. 2023. 30. 1. 37-42
-
中村 壮, 江藤 浩之. iPS細胞由来血小板製剤の開発. 検査と技術. 2023. 51. 1. 44-47
-
杉本 直志, 中村 壮, 江藤 浩之. 【血液疾患と血球分化】血小板産生における流体力学機序 乱流による血小板大量産生. 血液内科. 2021. 82. 1. 23-29
-
中村 壮, 江藤 浩之. 新規物理化学制御機構が1,000億個の血小板作製を可能にする. 臨床血液. 2020. 61. 6. 628-633
-
高石 浩司, 武内 正博, 塚本 祥吉, 高山 直也, 大島 基彦, 中村 壮, 江藤 浩之, 岩間 厚志, 横手 幸太郎, 中世古 知昭, et al. iPS細胞由来巨核球系前駆細胞株を用いたアナグレリドによる血小板産生抑制機構の解明. 日本臨床分子医学会学術総会プログラム・抄録集. 2019. 56回. 53-53
more...
Return to Previous Page